Related Experiment Video
Updated: Jul 15, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Amyloidosis in transgenic mice expressing murine amyloidogenic apolipoprotein A-II (Apoa2c)
Fengxia Ge1, Junjie Yao, Xiaoying Fu
1Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan.
Abstract:
In mice, apolipoprotein A-II (apoA-II) self-associates to form amyloid fibrils (AApoAII) in an age-associated manner. We postulated that the two most important factors in apoA-II amyloidosis are the Apoa2(c) allele, which codes for the amyloidogenic protein APOA2C (Gln5, Ala38) and transmission of amyloid fibrils. To characterize further the contribution of the Apoa2(c) allele to amyloidogenesis and improve detection of amyloidogenic materials, we established transgenic mice that overexpress APOA2C protein under the cytomegalovirus (CMV) immediate early gene (CMV-IE) enhancer/chicken beta promoter. Compared to transgene negative (Tg(-/-)) mice that express apoA-II protein mainly in the liver, mice homozygous (Tg(+/+)) and heterozygous (Tg(+/-)) for the transgene express a high level of apoA-II protein in many tissues. They also have higher plasma concentrations of apoA-II, higher ratios of ApoA-II/apolipoprotein A-I (ApoA-I) and higher concentrations of high-density lipoprotein (HDL) cholesterol. Following injection of AApoAII fibrils into Tg(+/+) mice, amyloid deposition was observed in the testis, liver, kidney, heart, lungs, spleen, tongue, stomach and intestine but not in the brain. In Tg(+/+) mice, but not in Tg(-/-) mice, amyloid deposition was induced by injection of less than 10(-8) mug AApoAII fibrils. Furthermore, deposition in Tg(+/+) mice occurred more rapidly and to a greater extent than in Tg(-/-) mice. These studies indicate that increased levels of APOA2C protein lead to earlier and greater amyloid deposition and enhanced sensitivity to the transmission of amyloid fibrils in transgenic mice. This transgenic mouse model should prove valuable for studies of amyloidosis.
Insights
Transgenic mice overexpressing APOA2C protein show increased amyloid deposition and sensitivity to amyloid fibril transmission. This model aids in studying apolipoprotein A-II amyloidosis.
Area of Science:
- Biochemistry
- Genetics
- Pathology
Background:
- Apolipoprotein A-II (apoA-II) self-associates into amyloid fibrils (AApoAII) in an age-dependent manner.
- The Apoa2(c) allele encodes the amyloidogenic APOA2C protein, a key factor in apoA-II amyloidosis.
- Amyloid fibril transmission is another critical factor in the development of apoA-II amyloidosis.
Purpose of the Study:
- To investigate the role of the Apoa2(c) allele in amyloidogenesis.
- To develop a transgenic mouse model for enhanced detection of amyloidogenic materials.
- To characterize the impact of APOA2C overexpression on amyloid deposition and fibril transmission.
Main Methods:
- Generation of transgenic mice overexpressing APOA2C protein under the CMV immediate early gene enhancer/chicken beta promoter.
- Comparison of amyloid deposition and fibril transmission in transgene-positive (Tg(+/+), Tg(+/-)) and transgene-negative (Tg(-/-)) mice.
- Administration of AApoAII fibrils to assess amyloid deposition in various tissues.
Main Results:
- Transgenic mice exhibited higher apoA-II levels, increased ApoA-II/ApoA-I ratios, and elevated HDL cholesterol.
- Amyloid deposition occurred in multiple organs (testis, liver, kidney, heart, lungs, spleen, tongue, stomach, intestine) in Tg(+/+) mice post-fibril injection.
- Tg(+/+) mice showed significantly enhanced amyloid deposition, faster onset, and greater extent compared to Tg(-/-) mice, even with minimal fibril inoculation.
Conclusions:
- Elevated APOA2C protein levels accelerate and amplify amyloid deposition.
- Increased APOA2C expression enhances susceptibility to amyloid fibril transmission.
- The developed transgenic mouse model is a valuable tool for studying apolipoprotein A-II amyloidosis.
